Specific inhibitors for vascular endothelial growth factor receptors
The present application describes isoindoles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful inhibitors of VEGFR.
1. A method of treating cancers having overexpressed VEGF, relative to normal tissue of the same type; overexpressed VEGF receptor, relative to normal tissue of the same type; or inhibiting angiogenesis in subjects with cancer, comprising: administering a therapeutically effective amount of the compound
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the cancer is selected from: breast, colorectal, lung, prostate, and ovarian.
3. A method of treating cancers having overexpressed VEGF, relative to normal tissue of the same type; overexpressed VEGF receptor, relative to normal tissue of the same type; or inhibiting angiogenesis in subjects with cancer, comprising: administering a therapeutically effective amount of the compound
or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the cancer is selected from: breast, colorectal, lung, prostate, and ovarian.
5. A method of treating cancers having overexpressed VEGF, relative to normal tissue of the same type; overexpressed VEGF receptor, relative to normal tissue of the same type; or inhibiting angiogenesis in subjects with cancer, comprising: administering a therapeutically effective amount of the compound
or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein the cancer is selected from: breast, colorectal, lung, prostate, and ovarian.